CN1709329A - Composition for treating female algomenorrhea and its preparing method - Google Patents

Composition for treating female algomenorrhea and its preparing method Download PDF

Info

Publication number
CN1709329A
CN1709329A CN 200510018887 CN200510018887A CN1709329A CN 1709329 A CN1709329 A CN 1709329A CN 200510018887 CN200510018887 CN 200510018887 CN 200510018887 A CN200510018887 A CN 200510018887A CN 1709329 A CN1709329 A CN 1709329A
Authority
CN
China
Prior art keywords
angelicae sinensis
radix angelicae
compositions
parts
rhizoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200510018887
Other languages
Chinese (zh)
Other versions
CN1321649C (en
Inventor
薛存宽
余作平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan United Pharmaceutical Co., Ltd.
Original Assignee
WUHAN LIANJIANG BIOTECHNOLOGY CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WUHAN LIANJIANG BIOTECHNOLOGY CO Ltd filed Critical WUHAN LIANJIANG BIOTECHNOLOGY CO Ltd
Priority to CNB2005100188878A priority Critical patent/CN1321649C/en
Publication of CN1709329A publication Critical patent/CN1709329A/en
Application granted granted Critical
Publication of CN1321649C publication Critical patent/CN1321649C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention discloses a Chinese medicine composition for effectively curing dysmenorrheal of women and its preparation method. Said Chinese medicine composition is made up by using the Chinese medicinal materials of valeriana officinalis and Chinese angelica root according to a certain ratio, and can be made into dripping pills or tablet or capsule or granules or ointment preparation. Said invention also provides the concrete steps of its preparation method.

Description

A kind of compositions and preparation method for the treatment of menalgia
Technical field
The invention belongs to treatment women's every value menstrual period or the front and back of passing through, lower abdomen pain occurs, or pain row waist sacrum, very then severe pain so that faintness person's gynecological field more specifically relates to a kind of compositions for the treatment of menalgia, the invention still further relates to the preparation method of said composition.
Background technology
This compositions cures mainly the pain of following menstruation.National woman month in 1978 is through the physical constants cooperative groups, and to the investigation and analysis through physical constants of 29 provinces and cities in the whole nation, municipal woman month more than 130,000, dysmenorrhea person accounts for 33.19%, slightly accounts for 45.73%, and moderate accounts for 12.81%, and severe accounts for 13.55%.
The medicine of treatment dysmenorrhea mainly contains at present:
1, chemicals
A. contraceptive
Oral contraceptive can reach therapeutic purposes by suppressing the prostaglandin level in the ovulation reduction blood, and 90% patient can remove symptom at medicining cycle.But contraceptive such as fugitive, long-acting, quick-acting all may cause the patient untoward reaction such as class morning sickness, moth patch on the skin, leucorrhoea grow in quantity, weight increase, spirit depressing, medicine erythra and hypertension to occur.Therefore, unless need contraception simultaneously, generally not as the TREATMENT OF DYSMENORRHOEA means.
B. PGSI
PGSI can reduce the release of prostaglandin, reduces uterus muscle contraction and spasm extent and eliminates dysmenorrhea.As long as before the pain outbreak, begin to take, got final product in lasting 2~3 days, but must try out a stage, determine medicament categories and optimum dosage that everyone curative effect is the most satisfied, the metamorphosis stage on probation is half a year sometimes.
PGSI commonly used can divide by its chemical constitution: 1. indoles: as indometacin, benzydamine hydrocloride; 2. fenamic acids: mefenamic acid, acidum clofenamicum, flufenamic acid; 3. phenylpropionic acid derivative: ibuprofen, naproxen (naproxan); 4. Phenylbutazone class: Phenylbutazone or crovaril.
The major side effects of such medicine is symptom of digestive tract and anaphylaxis, has digestive tract ulcer to reach the said medicine allergy sufferers is avoided.
C. calcium antagonist
Can stop calcium ion to pass through cell membrane, thereby suppress uterine contraction, nifedipine commonly used etc.This type of medicine major side effects has blood pressure drops, tachycardia, vasodilation headache and flush, generally not as drug of first choice.
2, Chinese patent medicine
1. JIAWEI XIAOYAOWAN:
Mainly form by Cortex Moutan, Radix Bupleuri, Radix Angelicae Sinensis, Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, stir-fry Herba Menthae etc.Have dispersing the stagnated live-QI to relieve the stagnation of QI, the effect of promoting blood flow to regulate menstruation is applicable to the dysmenorrhea companion through the fore udder distending pain, the susceptible to lose temper due to restlessness person.
2. Herba Leonuri paste
Mainly form by Herba Leonuri, Radix Angelicae Sinensis, the Radix Rehmanniae, Rhizoma Chuanxiong etc.Effect with promoting blood circulation to restore menstrual flow is applicable to dysmenorrhea companion blockage of menstruation, and color is dim, the person that has the clot.
3. YUANHU ZHITONG PIAN
Mainly consist of Rhizoma Corydalis.Effect with regulating QI to relieve pain is applicable to through row lower abdominal distention pain, fullness and distention in the chest and hypochondrium person.
4. dysmenorrhes ball
Mainly form by Oletum Trogopterori, Pollen Typhae, Rhizoma Corydalis, Radix Salviae Miltiorrhizae.Has blood circulation promoting and blood stasis dispelling, the effect of inducing menstruation to relieve menalgia.Be applicable to through the twinge of row lower abdomen, blockage of menstruation, clot is many, and clot is discharged back alleviation of pain person.
5, FUTONGNING drop pill: make by Radix Angelicae Sinensis oil, have the effect of relieving spasm to stop pain, be used for dysmenorrhes, puerperal uterine contraction pain, the acute chamber pain that infectious diarrhea causes etc.
There are defectives such as effective ingredient is imprecise, quality control level is low, taking dose is big, onset time is long, uncertain therapeutic efficacy is fixed in the Chinese patent medicine of above-mentioned various treatment dysmenorrheas.
The present composition is made up of Radix Angelicae Sinensis and Rhizoma et radix valerianae.Radix Angelicae Sinensis: be the dry root of umbelliferae angelica Angelicasinensis (Oliv.) Diels.Rhizoma et radix valerianae, latin name: Valeriana officinalis L. is the dry root and rhizome of Valerianaceae valeriana short, bristly hair or beard thing Rhizoma et radix valerianae.Main product in Sichuan, ground such as Hebei, Henan, Shandong, Shanxi, Taiwan, Hubei.Another name: deer grass, Rhizoma et radix valerianae.Wherein mainly contain volatile oil, main component is bornival (Bornyllsovalerate), valerone (Valer-anone) etc. in the oil.And contain the peaceful alkali (Valerianine) of volume grass, chatinine alkaloids such as (chatinine Chatinine), and valeric acid (Valeric Acld), isovaleric acid organic acid such as (lsovalericAcid), tannin, resin, cupreol etc.
Modern pharmacology proves: Radix Angelicae Sinensis has anticoagulant, antithrombotic, improves anemia and myocardial ischemia effect; Also have blood vessel dilating in addition, promote immunologic function, blood fat reducing, protect the liver, effect such as antiinflammatory.Clinically, Radix Angelicae Sinensis is mainly used in blood deficiency and yellow complexion, dizzy cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, ulcer sores, rheumatic arthralgia etc.Zoopery proves that Radix Angelicae Sinensis has the excitement of inhibition, strengthens shrinking dual-use function the uterus, and Radix Angelicae Sinensis is relevant with its chemical constituent and uterus functional status to the effect in uterus.The contained volatile oil component of Radix Angelicae Sinensis has inhibitory action to the uterus; The non-volatile alkaline components of its water solublity then has excitation to the uterus.When intrauterine pressurizeed, Radix Angelicae Sinensis was strengthened its contractility; When not pressurizeing, slight inhibitory action is arranged then.Adopt mouse writhing method, observe the influence of angelica essential oil Dichlorodiphenyl Acetate induced mice pain and female mice dysmenorrhea model; By to normal and show through the mice isolated uterine smooth muscle experiment that oxytocin is handled: angelica essential oil all has the obvious suppression effect to the mice pain due to female mice dysmenorrhea model and the acetic acid; To normal female mice isolated uterine smooth muscle with by violent contraction of the uterine smooth muscle due to the oxytocin obvious inhibitory action is also arranged all.(Liu Linna, Mei QiBing, Cheng Jianfeng, etc. the pharmacological research [J] of angelica essential oil treatment dysmenorrhea. PLA's Acta Pharmaceutica Sinica, 2002,18 (2): 77~78.)
Rhizoma et radix valerianae has pharmacologically active and long medication history widely, and it uses as tranquilizer and is of long duration.Recently, Germany, Holland, Japan have carried out a large amount of activity and Chemical Decomposition research, show Rhizoma et radix valerianae than synthetic drug commonly used at present as 2,3-phenylpropyl alcohol diazine (benzodiazepines) has the sedation effect gentleness, advantages such as no drug dependence and addiction.Rhizoma et radix valerianae has been recorded in the pharmacopeia of many European countries at present.
Chevalier studies show that, the Rhizoma et radix valerianae sedation effect is definite, and its main activity comes from the volatile oil component.Thies isolated valepotriate in 1966, and had confirmed its sedative activity by experiment.Active clinical trial shows Leathwood to the Rhizoma et radix valerianae water extract: Rhizoma et radix valerianae extract can reduce experimenter's time for falling asleep and objectively improve sleep quality.Hendriks further specifies valerenic acid and is very similar to pentobarbital (sedative activity index), thereby probably antidepressant activity is arranged also but not muscle relaxant activities.To the broad research of Rhizoma et radix valerianae chemistry and pharmacologically active,, also laid solid foundation for the exploitation of medication of valerian for medication of valerian enters the clinical basis in early stage of having established.On German drug market, have 57 kinds of Rhizoma et radix valerianae patent medicine at present as tranquilizer listing (folk prescription and compound recipe).In addition, Rhizoma et radix valerianae also has the releasing smooth muscle spasm, coronary artery dilator blood vessel and kidney, effects such as skin and striate blood vessel.It can also reduce myocardial oxygen consumption, has loose reaching with spasmolysis that bronchial smooth muscle is had certain diastole effect to the intestinal smooth muscle.But before the present invention, the no-trump Rhizoma et radix valerianae is used for the research report of menalgia treatment.
Summary of the invention
The object of the present invention is to provide a kind of compositions for the treatment of menalgia, its prescription rationally, effective ingredient is clear and definite, curative effect is definite, onset is rapid, non-evident effect.
Another object of the present invention provides a kind of preparation treatment menalgia method for compositions, and the effective ingredient of extraction is determined, method is easy to implement, applicable to large-scale production.
Medicine of the present invention is made by weight by following raw materials according:
Rhizoma et radix valerianae 1-95 part Radix Angelicae Sinensis 1-95 part
Medicine of the present invention is made by weight by following raw materials according:
Rhizoma et radix valerianae 1-95 part Radix Angelicae Sinensis 1-95 part
The prescription of present composition weight part ratio preferably is:
Rhizoma et radix valerianae 1-9 part Radix Angelicae Sinensis 1-9 part
The formula optimization weight part ratio of medicine of the present invention is:
1 part of 3 parts of Radix Angelicae Sinensis of Rhizoma et radix valerianae
To achieve these goals, the present invention takes following technical measures:
1, the radix valerianae that will after autumn gather and root stock flush away silt particle dry naturally to moisture and are lower than 12%, cut into the 2-4cm section;
2, insert extraction pot, adopt water isolation type water vapour distillation valerian naphtha.Time 1-6 hour, steam pressure was 0.01-0.15mPa/cm 2
3, will distill the valerian naphtha alcohol extraction that obtains 2-4 time, add 50~95% alcohol extraction 1-4 hours of 1~5 times of amount at every turn, leave standstill to the separation of oil-alcohol after each extraction, merge pure phase;
4, decompression recycling ethanol and leave standstill and treat oil-separated form water promptly gets valerian naphtha after abandoning water;
5, insert extraction pot after the Radix Angelicae Sinensis medical material is cut into the 0.2-1cm sheet, adopt water isolation type water vapour distillation Radix Angelicae Sinensis volatile oil, extraction time 1-6 hour, steam pressure was 0.01-0.10mPa/cm 2
6, will distill the Radix Angelicae Sinensis volatile oil that obtains and further do the rectification under vacuum processing, the composition of leaving and taking 140 ℃-280 ℃ of boiling points gets Radix Angelicae Sinensis volatile oil;
7, get step 4 gained valerian naphtha and step 6 gained Radix Angelicae Sinensis volatile oil mix homogeneously, obtain a kind of compositions;
8, make dosage forms such as capsule, drop pill, tablet, granule, unguentum according to clinical needs with step 7 compositions.
Compositions (proportioning of Rhizoma et radix valerianae and Radix Angelicae Sinensis is 3: 1) with the present invention has been carried out the spasmolysis to the animal isolated uterine, to the spasmolysis of animal in the body uterus, align the influence of the body uterus movement of being everlasting, the pharmacodynamic study of aspects such as calmness-analgesic activity and antiinflammatory.
In experiment to the isolated uterine spasmolysis, with the negative contrast of normal saline, with the positive contrast of present conventional Chinese medicine " FUTONGNING drop pill " (active ingredient is a Radix Angelicae Sinensis volatile oil), confirmed that this compositions has significant spasmolysis to the Cavia porcellus of exsomatizing, rat uterus smooth muscle.When final concentration is 10-160mg/L, inductive guinea pig in vitro uterus, the palace of contracting is continued spasm present intimate collinear spasmolytic amount (concentration)-effect relationship.Its about 1/2min of effect time that begins, during 5min near or reach spasmolysis in the peak, ED 50(median effective dose)=8.28mg/L, only be equivalent to " FUTONGNING " 1/30.In this experiment, " FUTONGNING " reducing the spasm tensile while of uterus, still exist more intensive rhythmicity to shrink, and this compositions do not existed tangible rhythmicity to shrink in the reduction spasm tensile while of uterus.
In to the experiment of normal rabbits in body uterus movement influence, with the negative contrast of normal saline, with " FUTONGNING " positive contrast, confirm that this compositions 10mg/Kg can make uterotonic frequency and pressure obviously descend, observe this compositions to of the influence of estrogen rabbit with uterus fistulation method at body uterus proper motion, data shows: though the negative control group rabbit gives that uterotonic frequency and pressure have fluctuation behind the normal saline, and there was no significant difference (p>0.05) between basic value; Positive controls gives the uterotonic frequency in " FUTONGNING drop pill " back and obviously reduces, and has significant difference between basic value own and negative control group (p<0.05); This compositions of 10mg/Kg is irritated stomach can make uterotonic frequency and pressure obviously descend, and has significance or utmost point significant difference (p<0.05 or p<0.01) between basic value own and negative control group.
To in the experiment of body uterus spasmolysis, with " FUTONGNING " positive contrast, confirm that this compositions has outstanding preventive and therapeutic effect to the mice that oxytocin causes at the body hysterospasm, and having tangible dose dependent, its action effect is compared with " FUTONGNING " matched group has significant difference (p<0.05).
In calmness-analgesic activity experiment, with the negative matched group of normal saline, with the positive matched group of chlorpromazine, the mice that the result confirms to irritate this compositions of stomach not only autonomic activities number of times obviously reduces, and active intensity also significantly weakens, point out this compositions to have certain sedation, and this effect have tangible dose dependent.Adopt writhing method to observe the analgesic activity of this compositions, the result shows that this compositions has certain analgesic activity, and this effect has tangible dose dependent relation.
Observe the antiinflammatory action of this compositions with the auricle edema method.The result shows that this compositions has certain antiinflammatory action, and this effect has tangible dose dependent relation.
We have also carried out toxicologic study with the present invention's compositions:
A, toxicity test basic condition:
Be subjected to the reagent thing to be this compositions, promptly Rhizoma et radix valerianae and Radix Angelicae Sinensis (3: 1) extract valerian naphtha and Radix Angelicae Sinensis volatile oil respectively, add an amount of olive oil dilution.Every Mus is irritated the stomach volume and is 0.4ml, and be 7.2h dead observing time.Each common reaction of organizing mice suppresses for the central nervous system and the peripheral blood vessel expansion, deepens to be narcotism with the increase inhibition of dosage, and even breathes severe inhibition and death.Calculate its LD according to karber's method 50Be 2149.5mg/Kg, the predetermined clinical using dosage of this compositions is 1.5~2.0mg/Kg. time, 4.5~6.0mg/Kg. day, so safety coefficient is very big.
B, test objective
Observe the disposable acute toxic reaction, death condition and the acute lethal reason that are produced behind the animal of giving of this compositions.According to LD 50, the ED that measures in conjunction with pharmacodynamics test 50Reach clinical medicine dose and judge the safe gradient of this new drug, and guide the dosage of long term toxicity test to select.
C, be subjected to the reagent thing
1. Rhizoma et radix valerianae and Radix Angelicae Sinensis extracted volatile oil respectively by weight 3: 1, were provided by the old medicine and pharmacology institute of Tongji Medical College, Huazhong Science and Technology Univ., and lot number is 20040712.
2. the configuration of medicament and content: above-mentioned valerian naphtha and Radix Angelicae Sinensis volatile oil mix, get miscella 5.25g and be 1. number liquid 30ml with olive oil dilution, concentration is 175mg/ml, get 1. number liquid 25.5ml and be 2. number liquid with olive oil 4.5ml dilution, according to this method prepare in proper order 3., 4., 5., 6. number liquid.1.~6. the filling stomach dosage of number liquid divides other to be 3.500g/Kg, 2.975g/Kg, 2.529g/Kg, 2.149g/Kg, 1.827g/Kg, 1.553g/Kg (irritate the stomach volume and be 0.4ml), and every group of spacing is 0.85.1.~6. the log10 dose of group filling stomach is respectively log0.5441,0.4735,0.4029,0.3322,0.2671,0.1912g/Kg, and a difference i is 0.0706.
3. laboratory animal: Kunming mouse, male and female half and half, body weight 20.0 ± 0.5g, is provided credit number SCXK2003-0005 by 10 every group by Ministry of Public Health institute of biological products Experimental Animal Center.1.~6.~1.~6. mice by grasping grouping at random, each 5 of every group of male and female.
D, experimental technique and result
1. route of administration: take and clinical consistent gastric infusion.
2. preliminary experiment: gastric infusion is observed 48h, records DM3.5g/Kg, DN1.6g/Kg.
3. dosage grouping: according to experimental result DM3.5g/Kg, DN1.6g/Kg, DM/DN=2 ±, always organize number and be decided to be 6, every group of spacing is 0.85, and every group of dosage is respectively 3.500g/Kg, 2.975g/Kg, 2.529g/Kg, 2.149g/Kg, 1.827g/Kg, 1.553g/Kg.
4. observe the time limit: observed 7 days behind the gastric infusion, be limited to 72h during necrology.
5. experiment condition: water 5h is can't help in fasting before the gastric infusion, and male and female are 5/cage group support separately, and the water of freely ingesting is raised 20~22 ℃ of room temperatures, humidity 40%.
6. the reaction of experimental mouse after the perfusion: medicament is irritated and respectively to be organized Mus in the stomach initial number hour and all present in various degree inhibitory state, the water of not ingesting, and few moving even paralysis crouches, and auricle and tail are significantly congested.2.975g/Kg above dosage group part Mus presents narcotism, bradypnea and irregular, skeletal muscle relaxation, increase with dosage that the generation ratio is high more, situation is serious more, most of death times occur in 18~48h, dead Mus separate treat others for earnest, lung, liver, kidney, gastrointestinal and brain naked eyes show no obvious abnormalities.The phenomena of mortality do not take place behind the 60h again.72h plays 1.553g/Kg group Mus near movable normal, and the following dosage group of 2.529g/Kg remains Mus alive and also begins the water of ingesting that reactivates.
7. animal dead situation:
Death time 3.500g/Kg 2.975g/Kg 2.529g/Kg 2.149g/Kg 1.827g/Kg 1.553g/Kg is only taught in death
????0~12h ????4 ????3 ????0 ????0 ????0 ????0
????12~24h ????2 ????3 ????1 ????1 ????2 ????0
????24~36h ????3 ????1 ????2 ????1 ????0 ????0
????36~48h ????1 ????1 ????2 ????1 ????0 ????0
????48~60h ????0 ????1 ????2 ????1 ????1 ????0
????60~72h ????0 ????0 ????0 ????1 ????1 ????0
????>72h ????0 ????0 ????0 ????0 ????0 ????0
Dead do not have obvious relation with sex, and the cause of death highly suppresses to cause breath cycle to stop for the central nervous system.
8. experimental data and statistical procedures (karber's method):
Drug dose (g/Kg) Log10 dose (log g/Kg) Number of animals (only) Death toll (only) Mortality rate (P i) ??X i+x i+1 ??P i+1-p i ??(X i+x i+1) ??×(P i+1- ????p i)
??3.500 ????0.5441 ??10 ??10 ????1.0 ????∑0.6647
??2.975 ????0.4735 ??10 ??9 ????0.9 ??1.0176 ????0.1 ????0.1018
??2.529 ????0.4029 ??10 ??7 ????0.7 ??0.8764 ????0.2 ????0.1753
??2.149 ????0.3322 ??10 ??5 ????0.5 ??0.7351 ????0.2 ????0.1470
??1.827 ????0.2617 ??10 ??4 ????0.4 ??0.5939 ????0.1 ????0.0594
??1.553 ????0.1912 ??10 ??0 ????0.0 ??0.4529 ????0.4 ????0.1812
Annotate: X i+ x I+iTwo adjacent groups logarithm concentration and; P I+1-p iThe dead rate variance of two adjacent groups
Median lethal dose(LD 50) LD 50Calculate---
lgLD 50=1/2∑(X i+x i+1)(P i+1-p i)
=1/2(0.6647)
=0.33235
LD 50=lg -10.33235
=2.1495(g/Kg)
LgLD 50Standard error SlgLD 50Calculate---
= 0.0969 × 0 / 9 + 0.09 / 9 + 0.21 / 9 + 0.25 / 9 + 0.24 / 9 + 0 / 9
= 0.0969 × 0.2963
= 0.0287
(d: two adjacent groups logarithm concentration difference; n i-1: the group degree of freedom)
LD 5095% fiducial limit=lg -1(lgLD 50± 1.96SlgLD 50)
=lg -1(0.33435±0.05625)
=lg -1(0.2781~0.3906)
=1.8972~2.4582(g/Kg)
9. acute toxicity test brief summary:
The LD of this compositions mouse stomach 50Value is 2.1495g/Kg;
LgLD 50Standard error be 0.0287;
LD 5095% credible 1.8972~2.4582 (g/Kg) that are limited to
The present invention compared with prior art has the following advantages and effect:
1. adopt Rhizoma et radix valerianae and work as to be grouped into compositions, effective component extracting---valerian naphtha and Radix Angelicae Sinensis volatile oil, definite effect, the preparation taking dose is easy to be accepted by the patient less than the existing medicine of great majority;
2. show through experiment that the preparation onset time weak point that the present invention obtains is fit to the requirement of dysmenorrhea patient quickly alleviating pain;
3. experiment confirm, the preparation toxic and side effects that the present invention obtains is minimum, relatively is fit to the women with existing chemical drugs and is used for dysmenorrhea treatment;
4. Rhizoma et radix valerianae and Radix Angelicae Sinensis are combined into compositions obviously is better than Radix Angelicae Sinensis or Rhizoma et radix valerianae to the spasmolysis of uterine smooth muscle independent effect;
5. because Rhizoma et radix valerianae has calmness, sedative action, have remarkable result, and this effect is to have treatment dysmenorrhea product at present to lack for psychentonia that improves the dysmenorrhea patient and sleep.
The specific embodiment
Embodiment 1:
1 part of 3 parts of Radix Angelicae Sinensis of Rhizoma et radix valerianae
Its preparation process is:
1, the bright radix valerianae that will after autumn gather and root stock flush away silt particle dry naturally to moisture and are lower than 12%, and cut into the 2-4cm section;
2, insert extraction pot, adopt water isolation type water vapour distillation valerian naphtha.3 hours time, steam pressure is 0.06mPa/cm 2
3, will distill the valerian naphtha alcohol extraction that obtains 2 times, add 70% alcohol extraction 2 hours of 3 times of amounts at every turn, leave standstill to the separation of oil-alcohol after each extraction, merge pure phase;
4, decompression recycling ethanol and leave standstill and treat oil-separated form water promptly gets purified valerian naphtha after abandoning water.
5, insert extraction pot after the Radix Angelicae Sinensis medical material is cut into the 0.2-0.5cm sheet, adopt water isolation type water vapour distillation Radix Angelicae Sinensis volatile oil, 2 hours extraction times, steam pressure is 0.08mPa/cm 2
6, will distill the Radix Angelicae Sinensis volatile oil that obtains and further do the rectification under vacuum processing, the composition of leaving and taking 160 ℃ of boiling points promptly gets makes with extra care Radix Angelicae Sinensis volatile oil;
7, get step 4 gained valerian naphtha and mix with step 6 gained Radix Angelicae Sinensis volatile oil, get miscella, add Tween 80 (miscella and Tween 80 weight ratio are 1: 1) in the miscella, mix homogeneously gets mixture;
8, taking polyethylene glycol 6000 (weight ratio of polyethylene glycol 6000 and step 7 gained mixture is 3.5: 1) adds the abundant mix homogeneously of step 7 gained mixture 80 ℃ of thawings;
9, step 8 mixture is placed drilling pill device, make drop pill, the heavy 20mg of every ball.
Embodiment 2 (consumption is a weight portion)
1 part of 9 parts of Radix Angelicae Sinensis of Rhizoma et radix valerianae
Preparation process is identical with embodiment 1.
Embodiment 3 (consumption is a weight portion)
1 part of Rhizoma et radix valerianae, 3 parts of Radix Angelicae Sinensis
Preparation process is identical with embodiment 1.
Embodiment 4 (consumption is a weight portion)
6 parts of Rhizoma et radix valerianaes, 1 part of Radix Angelicae Sinensis
Preparation process is identical with embodiment 1.
Embodiment 5 (consumption is a weight portion)
20 parts of Rhizoma et radix valerianaes, 1 part of Radix Angelicae Sinensis
Preparation process is identical with embodiment 1.
Embodiment 6 (consumption is a weight portion)
9 parts of Rhizoma et radix valerianaes, 1 part of Radix Angelicae Sinensis
Preparation process is identical with embodiment 1.
Embodiment 7 (consumption is a weight portion)
3 parts of Rhizoma et radix valerianaes, 1 part of Radix Angelicae Sinensis
Preparation process is identical with embodiment 1.
Embodiment 8 (consumption is a weight portion)
1 part of Rhizoma et radix valerianae, 1 part of Radix Angelicae Sinensis
Preparation process is identical with embodiment 1.

Claims (10)

1, a kind of compositions that is used for the treatment of menalgia, it is made by following raw materials in parts by weight:
Rhizoma et radix valerianae 1-95 part Radix Angelicae Sinensis 1-95 part.
2, a kind of compositions that is used for the treatment of menalgia according to claim 1 is characterized in that it is made by following raw materials in parts by weight:
Rhizoma et radix valerianae 1-50 part Radix Angelicae Sinensis 1-50 part.
3, a kind of compositions that is used for the treatment of menalgia according to claim 1 is characterized in that it is made by following raw materials in parts by weight:
1 part of 20 parts of Radix Angelicae Sinensis of Rhizoma et radix valerianae.
4, a kind of compositions that is used for the treatment of menalgia according to claim 1 is characterized in that it is made by following raw materials in parts by weight:
1 part of 9 parts of Radix Angelicae Sinensis of Rhizoma et radix valerianae.
5, a kind of compositions that is used for the treatment of menalgia according to claim 1 is characterized in that it is made by following raw materials in parts by weight:
1 part of 6 parts of Radix Angelicae Sinensis of Rhizoma et radix valerianae.
6, a kind of compositions that is used for the treatment of menalgia according to claim 1 is characterized in that it is made by following raw materials in parts by weight:
1 part of 3 parts of Radix Angelicae Sinensis of Rhizoma et radix valerianae.
7, a kind of compositions that is used for the treatment of menalgia according to claim 1 is characterized in that it is made by following raw materials in parts by weight:
1 part of 1 part of Radix Angelicae Sinensis of Rhizoma et radix valerianae.
8, a kind of compositions that is used for the treatment of menalgia according to claim 1 is characterized in that it is made by following raw materials in parts by weight:
3 parts of 1 part of Radix Angelicae Sinensis of Rhizoma et radix valerianae.
9, a kind of method for compositions that realizes the described preparation treatment of claim 1 menalgia, it comprises the following steps:
A, the bright radix valerianae that will after autumn gather and root stock flush away silt particle dry to moisture and are lower than 12%, and cut into the 2-4cm section;
B, insert extraction pot, adopt water isolation type water vapour distillation valerian naphtha, 1-6 hour, steam pressure was 0.01-0.15mPa/cm 2
C, will distill the valerian naphtha alcohol extraction that obtains 2-4 time, add 55~95% alcohol extraction 1-4 hours of 1~5 times of amount, leave standstill after the extraction, merge pure phase to the separation of oil-alcohol;
D, decompression recycling ethanol also leave standstill and treat oil-separated form water, promptly get valerian naphtha after abandoning water;
E, insert extraction pot after the Radix Angelicae Sinensis medical material is cut into the 0.2-1cm sheet, adopt water isolation type water vapour distillation Radix Angelicae Sinensis volatile oil, extracted 1-6 hour, steam pressure is 0.01-0.10mPa/cm 2
F, will distill the Radix Angelicae Sinensis volatile oil that obtains and further do rectification under vacuum and handle, the composition of leaving and taking 140 ℃-280 ℃ of boiling points promptly gets Radix Angelicae Sinensis volatile oil;
G, get step D gained valerian naphtha and mix promptly with step F gained Radix Angelicae Sinensis volatile oil.
10, a kind of compositions that is used for the treatment of menalgia according to claim 1 is characterized in that being respectively following dosage form:
A, drop pill;
B, tablet;
C, granule;
D, capsule;
E, unguentum.
CNB2005100188878A 2005-06-09 2005-06-09 Composition for treating female algomenorrhea and its preparing method Active CN1321649C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005100188878A CN1321649C (en) 2005-06-09 2005-06-09 Composition for treating female algomenorrhea and its preparing method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005100188878A CN1321649C (en) 2005-06-09 2005-06-09 Composition for treating female algomenorrhea and its preparing method

Publications (2)

Publication Number Publication Date
CN1709329A true CN1709329A (en) 2005-12-21
CN1321649C CN1321649C (en) 2007-06-20

Family

ID=35705661

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100188878A Active CN1321649C (en) 2005-06-09 2005-06-09 Composition for treating female algomenorrhea and its preparing method

Country Status (1)

Country Link
CN (1) CN1321649C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112472755A (en) * 2020-12-02 2021-03-12 武汉惠尔生物科技有限公司 Traditional Chinese medicine for treating dysmenorrhea and preparation method and application thereof
CN113004975A (en) * 2021-03-19 2021-06-22 湖南安邦制药股份有限公司 Method for extracting mixed volatile oil of angelica and fingered citron

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1079261C (en) * 1999-11-11 2002-02-20 中国科学院西北高原生物研究所 Medicinal composition for stopping narcotic taking and preparation process thereof
CN1135996C (en) * 2000-06-09 2004-01-28 红桃开集团股份有限公司 Chinese medicine for treating coronary heart disease and angina pectoris and its preparing process
CN1475490A (en) * 2003-07-31 2004-02-18 凯 曹 Valerian extract and its preparation method and use

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112472755A (en) * 2020-12-02 2021-03-12 武汉惠尔生物科技有限公司 Traditional Chinese medicine for treating dysmenorrhea and preparation method and application thereof
CN112472755B (en) * 2020-12-02 2022-06-07 武汉惠尔生物科技有限公司 Traditional Chinese medicine for treating dysmenorrhea and preparation method and application thereof
CN113004975A (en) * 2021-03-19 2021-06-22 湖南安邦制药股份有限公司 Method for extracting mixed volatile oil of angelica and fingered citron

Also Published As

Publication number Publication date
CN1321649C (en) 2007-06-20

Similar Documents

Publication Publication Date Title
CN1931353A (en) Curcuma extract and its prepn process, medicine composition and use
CN1824035A (en) Swim bladder kidney nourishing preparation and its preparation method
CN1775276A (en) Fushu Preparation and new preparing method
CN1748783A (en) Dismenorrhea preparation and new preparing method
CN1748748A (en) Little leaf deervetch herb preparation for pregnant woman and new preparing method
CN100341540C (en) Angelica root mistletoe granules and its preparation method
CN1709329A (en) Composition for treating female algomenorrhea and its preparing method
CN1966001A (en) Medicament for treating inflammation and preparation method thereof
CN1850253A (en) Qianjin-Baoyun preparation and novel preparing method
CN1879799A (en) Menstruation-regulating preparation with asiabell and cassia bark and method for preparing same
CN1437983A (en) Plaster for treating dysmenorrhoea and preparation method
CN1943694A (en) A Chinese traditional medicinal composition for treating renal deficiency, edema, lumbago and gonalgia, etc.
CN1775258A (en) Womb-warming pregnancy-aiding preparation and new preparing method
CN1748741A (en) Little leaf deervetch herb acne removing preparation and new preparing method
CN1824128A (en) Semen locking medicinal preparation and its new preparation method
CN1246016C (en) Compound formulation of traditional Chinese medicine for climacteric syndrome and preparation method
CN1824109A (en) Liaoyuanqili medicinal preparation and its new preparation method
CN1709381A (en) Medicinal composition for tonifying kidney and eliminating obstruction, and its preparing method
CN1824241A (en) Medicinal preparation and its new preparation method
CN1541691A (en) Acute icterohepatitis treating Chinese traditional medicine and its preparation
CN1824270A (en) Middle-jiao regulating medicinal preparation and its new preparation method
CN1225277C (en) Chinese medicinal composition for treating epilepsy disease and its preparation method
CN1748775A (en) Nujin preparation and new preparing method
CN101053624A (en) Traditional Chinese medicinal for treating prostatic hyperplasia and chronic prostatitis and its preparation process
CN1742824A (en) Gynaecological Desheng preparation and new preparation method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: WUHAN UNITED PHARMACY CO., LTD.

Free format text: FORMER OWNER: WUHAN LIANJIANG BIOTECHNOLOGY CO., LTD.

Effective date: 20100513

COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 430070 NO.465, LUOSHI ROAD, HONGSHAN DISTRICT, WUHAN CITY, HUBEI PROVINCE TO: 430074 NO.33, GUANSHAN ROAD 2, DONGHU DEVELOPMENT AREA, WUHAN CITY, HUBEI PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20100513

Address after: The East Lake development zone two road 430074 Hubei city of Wuhan province No. 33

Patentee after: Wuhan United Pharmaceutical Co., Ltd.

Address before: 430070 Hubei Province, Wuhan city Hongshan District Luoshi Road No. 465

Patentee before: Wuhan Lianjiang Biotechnology Co., Ltd.